RxDoctor Payments Data

Staci Dunn

Family · Knoxville, TNNPI 1194289835

Payments from drug & device makers

$7,295in general payments, 2019–2025

Across 454 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$824
  • Boston Scientific$716
  • Impel Pharmaceuticals Inc.$578
  • Collegium Pharmaceutical, Inc.$570
  • Biohaven Pharmaceutical Holding Company Ltd.$456
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$7,24699%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,295 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$11,741
Medicare patients
147
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate110$49,664
UbrelvyUbrogepant18$27,149
OxycontinOxycodone Hcl57$24,102
QuliptaAtogepant17$17,860
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen551$13,655
ZtlidoLidocaine19$12,445
Aimovig AutoinjectorErenumab-Aooe12$11,639
BelbucaBuprenorphine Hcl13$10,429
Hysingla ErHydrocodone Bitartrate15$7,063
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen277$6,230
Lidocaine49$5,941
SymproicNaldemedine Tosylate12$5,536
Fentanyl37$5,532
Oxycodone Hcl267$5,035
MovantikNaloxegol Oxalate12$4,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$570$60,093123 claims
AbbVieUbrelvy, Qulipta$1,329$45,00835 claims
Scilex Pharmaceuticals Inc.Ztlido$241$12,44519 claims
Redhill Biopharma Inc.Movantik$26$4,75812 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$142$4,55340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →